Video: Les Benet on Hurel
Dr. Benet’s July, 2013 presentation to The Boston Society, “Hepatic Artificial Tissue Constructs Affording Interspecies Comparison of DMPK Endpoints in Human, Rat and Dog,” reviews and compares 21-day characterization data of the HµRELhumanTM, HµRELdogTM, and HµRELratTM primary cell-based hepatic co-cultures, demonstrating the products’ abilities to correlate in vitro with in vivo results and to model interspecific differences of response to reference compounds known to clear and to generate primary and secondary metabolites differentially in different species in vivo. The running time of the presentation is approximately seventeen minutes.

A Hurel video case study
Clarinex®: The Hunt for the Unproducible Metabolite
Ronald E. White, Ph.D., President, White Global Pharma Consultants, LLC
Formerly Vice President of Drug Metabolism, Schering-Plough Research Institute, Dr. White was directly engaged in the pre-clinical development of desloratadine (Clarinex®), the second-generation drug that Schering developed to follow its blockbuster medication, loratadine (Claritin®). Dr. White’s case study traces the research challenges Schering faced in attempting to answer the FDA’s questions about 3-hydroxy desloratadine, a circulating metabolite which in vitro models then available to Schering were unable to generate but which the HµRELhumanTM model was shown to produce successfully. It also comments on how a correctly predictive in vitro tool like Hurel might have affected the economics of the commercial launch of Clarinex®. The video runs about four minutes. A downloadable white paper printed version is also available.

multi-readout, repeat-dose
DILI screening
DILI screening

Hurel microlivers afford better prediction than 3D

Toxicology Research
Long-enduring infectious liver disease platform
Toxicity Ratios*
A new marker for hepatotoxic chronicity

*patent pending
a new, patent-pending
efflux transport
assay method
Superior intrinsic clearance
and biotransformation of
low-turnover drugs